Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader ...

Shares of Merck & Co. Inc. MRK rallied 2.08% to $89.50 Friday, on what proved to be an all-around rough trading session for ...

Data presented at key congresses in North America and EuropeCAMBRIDGE, United Kingdom, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Microbiotica, a cl ...

Additional data from CheckMate 274 showed that adjuvant nivolumab benefits patients with muscle-invasive bladder cancer with ...

Vancouver-based Variational AI has raised US$5.5 million in an oversubscribed funding round and plans to double its ...

Merck & Co. is facing its first jury trial over claims the company wrongfully marketed its lucrative Gardasil cancer vaccine as safe, the latest high-stakes litigation for the pharmaceutical giant.

February 20, 2025) - The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Merck & Co., Inc. (NYSE: MRK) securities between February 3, 2022 and February 3, 2025, ...

FDA approves an expanded access program that would offer patients an alternative to Merck’s bladder cancer medication.

Researchers identify a new player in human immunity that can go rogue and turn the immune system against the body’s own ...

Compute efficient generative AI foundation model for small molecule drug discovery start-up announces funding from leading AI ...

NEW YORK, NY / ACCESS Newswire / February 19, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn ...

The nitrogen trifluoride (NF3) market expands with semiconductor and display manufacturing demand, driven by pr ...